Wuhan Hiteck Biological Pharma Co.,Ltd reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was CNY 131.89 million compared to CNY 138.64 million a year ago. Revenue was CNY 131.89 million compared to CNY 138.64 million a year ago.

Net loss was CNY 16.55 million compared to CNY 1.47 million a year ago. Basic loss per share from continuing operations was CNY 0.13 compared to CNY 0.02 a year ago. Diluted loss per share from continuing operations was CNY 0.13 compared to CNY 0.02 a year ago.